- Viral Culture Test
- Nucleic acid amplification test (NAAT)
- And Anti-Biotic Test
Herpes Simplex Virus Diagnostics Market is expected to grow at a CAGR of 6.4% from 2024 to 2030, from a market size of USD 389.5 million in 2023 due to the expansion of the HSV diagnostics market. Covid-19 is the main reason for expansion, where researchers have identified the link between the herpes simplex virus and the SARS-CoV-2 virus in various studies, and a rising number of HSV infections, according to the WHO estimates that 3.7 billion people under 50 have HSV-1, and 491.5 million people aged 15-49 live with HSV-2, indicating a significant and growing population requiring diagnosis, as people become increasingly informed about the potential consequences of HSV infection, they are more likely to seek testing, driving the herpes simplex virus diagnostics market demand for diagnostics, the development of newer, more accurate HSV tests with improved sensitivity and specificity is facilitating more precise and reliable diagnoses.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
High prevalence of the virus, increasing public awareness, and advancements in rapid testing technology such as nucleic acid amplification tests (NAAT), detect the presence of the viral DNA and are highly sensitive and specific, and most commonly used tests for HSV diagnosis. However, social stigma and inconsistent reimbursement policies pose challenges. The market holds promise in emerging regions such as Asia-Pacific, and Latin America with growing healthcare infrastructure and rising disposable income, and the development of multiplex tests for multiple STIs could further increase accessibility and market growth.
The global herpes simplex virus (HSV) diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030, from a market size of USD 389.5 million in 2023.
Abbott Laboratories (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), BD (Becton, Dickinson and Company) (US), Hologic, Inc. (US), Qiagen (Netherlands), Seegene Inc. (South Korea), Agenus Inc. (U.S.), Maruho Co., Ltd. (Japan), Sanofi (France) Norgen Biotek Corp. (Canada), Bio-Rad Laboratories, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Teco Diagnostics (U.S.), and GSK plc. (U.K.)
Asia-Pacific is the fastest growing and North America is the dominant market in HSV diagnostics.